Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | JAK1 | P23458 | 5/20 | 0.42 |
| ▸ | TYK2 | P29597 | 5/20 | 0.42 |
| ▸ | JAK3 | P52333 | 5/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CLK1 | P49759 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23390448 | 0.89 | AHR (0.42) | JAK2JAK1TYK2JAK3AHR | |
| SCHEMBL23390451 | 0.89 | AHR (0.42) | JAK2JAK1TYK2JAK3AHR | |
| SCHEMBL23925513 | 0.89 | TYK2 (0.40) | JAK2JAK1TYK2JAK3FGFR3 | |
| SCHEMBL23950588 | 0.84 | PSD (0.41) | CNR1CYP3A4GAA | |
| SCHEMBL23390288 | 0.83 | FGFR3 (0.38) | JAK2JAK1TYK2JAK3AHR | |
| SCHEMBL23390162 | 0.83 | FGFR3 (0.38) | JAK2JAK1TYK2JAK3AHR | |
| SCHEMBL23390159 | 0.83 | FGFR3 (0.38) | JAK2JAK1TYK2JAK3AHR | |
| SCHEMBL23950286 | 0.82 | AHR (0.41) | AHRCNR1 | |
| SCHEMBL29738280 | 0.82 | AHR (0.41) | JAK2JAK1TYK2JAK3AHR | |
| SCHEMBL23950561 | 0.82 | BRD4 (0.43) | CNR1CNR2FGFR3KDRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115443276-B | Pyridopyrimidinone derivatives and their use as arene receptor modulators | 东亚ST株式会社 | 2025-04-18 | — | — | CN | claimed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | claimed |
| EP-4136088-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-22 | — | — | EP | claimed |
| WO-2021210970-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2021-10-21 | — | — | WO | claimed |
| CN-115443276-B | Pyridopyrimidinone derivatives and their use as arene receptor modulators | 东亚ST株式会社 | 2025-04-18 | — | — | CN | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4136088-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-22 | — | — | EP | disclosed |
| CN-115443276-A | Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors | 东亚ST株式会社 | 2022-12-06 | — | — | CN | disclosed |
| WO-2021210970-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | JAK2 919/4885JAK1 2330/4885TYK2 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.